Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - NETs and endocrine tumours

1101MO - Development of CAR T-cells for future treatment of NETs

Date

20 Sep 2021

Session

Mini oral session - NETs and endocrine tumours

Presenters

Barbara Mandriani

Citation

Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016/annonc/annonc678

Authors

B. Mandriani1, E. Pelle'1, F. Mannavola2, G. Ingravallo1, G. Cazzato3, M.C. Ramello4, C.G. Porta1, J.R. Strosberg5, D. Abate-Daga4, M. Cives1

Author affiliations

  • 1 Department Of Biomedical Sciences And Human Oncology, Università degli Studi di Bari Aldo Moro, 70123 - Bari/IT
  • 2 Medical Oncology Unit, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70124 - Bari/IT
  • 3 Pathology Unit, Policlinico Of Bari, Bari/IT
  • 4 Immunology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 5 Gi Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1101MO

Background

Neuroendocrine tumors (NETs) overexpress somatostatin receptors (SSTRs). We investigated the antitumor activity of chimeric antigen receptor (CAR) T cells directed against SSTRs.

Methods

A second-generation CAR-like construct containing two molecules of octreotide in the extracellular moiety and CD28 as costimulatory module was cloned in a pMSGV1-28Z retroviral vector and then transduced in human T cells. Luciferase+ (Luc+) BON1, CM, QGP1, CNDT2.5 and H727 NET cell lines were screened for membrane SSTR2/5 expression by Western blot (WB) and flow cytometry. Co-culture experiments were performed at effector:target (E:T) ratios ranging from 50:1 to 1:50 for up to 72 hrs. Tumor cell cytotoxicity was assessed by bioluminescence imaging. The release of IFN-γ and IL-2 by activated CAR T cells was investigated by ELISA. NSG female mice (n=11/group) were subcutaneously injected with 2x106 Luc+ BON1 or CM cells, and were then intravenously treated either with 7x106 anti-SSTR CAR T cells, or untransduced (UT) T cells. Excised tumors were subjected to PCR to assess the infiltration of CAR T cells. Potential on-target off-tumor toxicities of anti-SSTR CAR T cells were investigated by pathological analysis of mouse brain and pancreas.

Results

All NET cell lines expressed SSTR2/5, although at variable levels. Following WB confirmation of the CAR expression by transduced lymphocytes, anti-SSTR CAR T cells were co-incubated with target cells. Tumor cell death was induced in approximately 40% (±8%) of CM and BON1 cells at E:T ratio of 1:1. The tumoricidal effect of CAR T cells was time-dependent and peaked at 72 hrs. Compared with UT T cells, CAR T cells secreted significantly higher levels (p<0.01) of IFN-γ and IL-2 after co-incubation with NET cells. Anti-SSTR CAR T cells effectively infiltrated tumors and significantly reduced the growth of subcutaneous CM (p=0.01) and BON1 xenografts (p=0.02) in mice by in vivo bioluminescence imaging. No pathological alterations were seen in the brain and pancreas of mice treated with CAR T cells.

Conclusions

Anti-SSTR CAR T cells exert antitumor activity against SSTR+ NET cell lines, both in vitro and in vivo.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

ENETS, AIRC.

Disclosure

D. Abate-Daga: Non-Financial Interests, Personal, Advisory Board: Anixa Biosciences; Financial Interests, Personal and Institutional, Funding: Intellia Therapeutics; Financial Interests, Personal and Institutional, Funding: Bluebird bio. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.